175 related articles for article (PubMed ID: 22932799)
1. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?
Gallamini A; Kostakoglu L
Blood; 2012 Dec; 120(25):4913-20. PubMed ID: 22932799
[TBL] [Abstract][Full Text] [Related]
2. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
Adams HJ; Kwee TC
Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
[TBL] [Abstract][Full Text] [Related]
3. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
Kostakoglu L; Gallamini A
J Nucl Med; 2013 Jul; 54(7):1082-93. PubMed ID: 23818548
[TBL] [Abstract][Full Text] [Related]
4. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.
Le Roux PY; Gastinne T; Le Gouill S; Nowak E; Bodet-Milin C; Querellou S; Mahe B; Dubruille V; Blin N; Salaun PY; Bodere-Kraeber F
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1064-71. PubMed ID: 21308370
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
Hutchings M
Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
[TBL] [Abstract][Full Text] [Related]
7. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Blood; 2014 Nov; 124(23):3356-64. PubMed ID: 25428223
[TBL] [Abstract][Full Text] [Related]
8. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation.
Gallamini A; Fiore F; Sorasio R; Meignan M
Leuk Lymphoma; 2009 Nov; 50(11):1761-4. PubMed ID: 19883305
[TBL] [Abstract][Full Text] [Related]
9. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
10. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
[TBL] [Abstract][Full Text] [Related]
11. Early interim PET scan in Hodgkin lymphoma: where do we stand?
Gallamini A; Hutchings M; Avigdor A; Polliack A
Leuk Lymphoma; 2008 Apr; 49(4):659-62. PubMed ID: 18398732
[TBL] [Abstract][Full Text] [Related]
12. Role of PET in lymphoma.
Gallamini A; Borra A
Curr Treat Options Oncol; 2014 Jun; 15(2):248-61. PubMed ID: 24619427
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.
Hutchings M; Mikhaeel NG; Fields PA; Nunan T; Timothy AR
Ann Oncol; 2005 Jul; 16(7):1160-8. PubMed ID: 15939713
[TBL] [Abstract][Full Text] [Related]
14. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):135-43. PubMed ID: 25696846
[TBL] [Abstract][Full Text] [Related]
15. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
16. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.
Gallamini A; Hutchings M; Rigacci L; Specht L; Merli F; Hansen M; Patti C; Loft A; Di Raimondo F; D'Amore F; Biggi A; Vitolo U; Stelitano C; Sancetta R; Trentin L; Luminari S; Iannitto E; Viviani S; Pierri I; Levis A
J Clin Oncol; 2007 Aug; 25(24):3746-52. PubMed ID: 17646666
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
Kostakoglu L; Evens AM
Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
[TBL] [Abstract][Full Text] [Related]
19. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.
Adams HJA; Kwee TC
Semin Oncol; 2017 Dec; 44(6):404-419. PubMed ID: 29935902
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Aug; 170(3):356-66. PubMed ID: 25868485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
